ALK-Abelló A/S (AKBLF)
Market Cap | 4.46B |
Revenue (ttm) | 768.66M |
Net Income (ttm) | 113.14M |
Shares Out | n/a |
EPS (ttm) | 0.51 |
PE Ratio | 39.46 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 500 |
Average Volume | 398 |
Open | 21.35 |
Previous Close | 20.30 |
Day's Range | 21.35 - 21.35 |
52-Week Range | 10.95 - 26.45 |
Beta | 0.63 |
RSI | 38.81 |
Earnings Date | Feb 19, 2025 |
About ALK-Abelló
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healt... [Read more]
Financial Performance
In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.
Financial numbers in DKK Financial StatementsNews
ALK-Abelló projects 9%-13% revenue growth for 2025 driven by global tablet expansion
ALK-Abelló A/S (AKBLF) Q4 2024 Earnings Call Transcript
ALK-Abelló A/S reports FY results
Q3 2024 ALK-Abello A/S Earnings Call Transcript
Q3 2024 ALK-Abello A/S Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Q3 2024 Earnings Conference Call Transcript
ALK-Abelló A/S 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by ALK-Abelló A/S in conjunction with their 2024 Q3 earnings call.
ALK-Abelló A/S 2024 Q2 - Results - Earnings Call Presentation
ALK-Abelló A/S (AKBLF) Q2 2024 Earnings Call Transcript
ALK-Abelló A/S (OTCPK:AKBLF) Q2 2024 Earnings Conference Call August 23, 2024 7:30 AM ETCompany ParticipantsPer Plotnikof - Head of IRPeter Halling -...
ALK-Abelló A/S reports Q2 results; raises FY24 outlook

ALK upgrades its full-year revenue and earnings outlook
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remain...

ALK-Abelló A/S (AKBLF) Q1 2024 Earnings Call Transcript
ALK-Abelló A/S (OTCPK:AKBLF) Q1 2024 Results Conference Call May 3, 2024 6:30 AM ET Company Participants Per Plotnikof - Head of Investor Relations Peter Halling - Chief Executive Officer Claus Steens...

Invitation to the presentation of ALK's first quarter results on Friday 3 May 2024
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its first quarter results in the morning of 3 May 2024. Later same day, the company will host a presentation for investors and analysts at 12:30 CET, wh...

Release date of six-month interim report (Q2) 2023 for ALK and audio cast
On Thursday, 24 August 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its six-month interim report (Q2) 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CES...

ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook
ALK's (ALKB:DC / OMX: ALK B / AKBLF) overall results in Q1 2023 were largely as expected with 7% organic revenue growth in local currencies and increasing operating profit (EBIT). Combined SCIT and SL...